Esperion Therapeutics Debt

ESPR Stock  USD 2.54  0.03  1.17%   
At this time, Esperion Therapeutics' Debt To Assets are relatively stable compared to the past year. As of 11/28/2024, Long Term Debt To Capitalization is likely to grow to 11.31, though Debt To Equity is likely to grow to (1.12). . Esperion Therapeutics' financial risk is the risk to Esperion Therapeutics stockholders that is caused by an increase in debt.
 
Debt Ratio  
First Reported
2010-12-31
Previous Quarter
2.60633832
Current Value
2.74
Quarterly Volatility
1.25966542
 
Credit Downgrade
 
Yuan Drop
 
Covid
At this time, Esperion Therapeutics' Total Current Liabilities is relatively stable compared to the past year. As of 11/28/2024, Liabilities And Stockholders Equity is likely to grow to about 216.1 M, while Non Current Liabilities Other is likely to drop slightly above 120 M.
  
Check out the analysis of Esperion Therapeutics Fundamentals Over Time.
To learn how to invest in Esperion Stock, please use our How to Invest in Esperion Therapeutics guide.

Esperion Therapeutics Bond Ratings

Esperion Therapeutics financial ratings play a critical role in determining how much Esperion Therapeutics have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Esperion Therapeutics' borrowing costs.
Piotroski F Score
1
Very WeakView
Beneish M Score
(3.51)
Unlikely ManipulatorView

Esperion Therapeutics Debt to Cash Allocation

Many companies such as Esperion Therapeutics, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
Esperion Therapeutics currently holds 540.95 M in liabilities. Esperion Therapeutics has a current ratio of 3.01, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Esperion Therapeutics' use of debt, we should always consider it together with its cash and equity.

Esperion Therapeutics Total Assets Over Time

Esperion Therapeutics Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Esperion Therapeutics uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Esperion Therapeutics Debt Ratio

    
  274.0   
It seems most of the Esperion Therapeutics' assets are financed through debt. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Esperion Therapeutics' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Esperion Therapeutics, which in turn will lower the firm's financial flexibility.

Esperion Therapeutics Corporate Bonds Issued

Esperion Short Long Term Debt Total

Short Long Term Debt Total

567.99 Million

At this time, Esperion Therapeutics' Short and Long Term Debt Total is relatively stable compared to the past year.

Understaning Esperion Therapeutics Use of Financial Leverage

Esperion Therapeutics' financial leverage ratio measures its total debt position, including all of its outstanding liabilities, and compares it to Esperion Therapeutics' current equity. If creditors own a majority of Esperion Therapeutics' assets, the company is considered highly leveraged. Understanding the composition and structure of Esperion Therapeutics' outstanding bonds gives an idea of how risky it is and if it is worth investing in.
Last ReportedProjected for Next Year
Short and Long Term Debt Total540.9 M568 M
Net Debt458.7 M481.6 M
Short Term Debt36.4 M38.2 M
Long Term Debt261.6 M274.7 M
Long Term Debt Total206.3 M216.6 M
Short and Long Term DebtM6.3 M
Net Debt To EBITDA(3.06)(2.90)
Debt To Equity(1.18)(1.12)
Interest Debt Per Share 5.77  6.06 
Debt To Assets 2.61  2.74 
Long Term Debt To Capitalization 10.77  11.31 
Total Debt To Capitalization 6.59  6.92 
Debt Equity Ratio(1.18)(1.12)
Debt Ratio 2.61  2.74 
Cash Flow To Debt Ratio(0.25)(0.27)
Please read more on our technical analysis page.

Pair Trading with Esperion Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Esperion Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Esperion Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Esperion Stock

  0.9BMY Bristol Myers Squibb Aggressive PushPairCorr

Moving against Esperion Stock

  0.84MRK Merck Company Fiscal Year End 6th of February 2025 PairCorr
  0.82NKTX Nkarta Inc Buyout TrendPairCorr
  0.77PEPG PepGenPairCorr
  0.72FDMT 4D Molecular TherapeuticsPairCorr
  0.72JNJ Johnson Johnson Fiscal Year End 28th of January 2025 PairCorr
The ability to find closely correlated positions to Esperion Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Esperion Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Esperion Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Esperion Therapeutics to buy it.
The correlation of Esperion Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Esperion Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Esperion Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Esperion Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Esperion Stock Analysis

When running Esperion Therapeutics' price analysis, check to measure Esperion Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Esperion Therapeutics is operating at the current time. Most of Esperion Therapeutics' value examination focuses on studying past and present price action to predict the probability of Esperion Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Esperion Therapeutics' price. Additionally, you may evaluate how the addition of Esperion Therapeutics to your portfolios can decrease your overall portfolio volatility.

What is Financial Leverage?

Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.

Leverage and Capital Costs

The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.

Benefits of Financial Leverage

Leverage provides the following benefits for companies:
  • Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
  • It provides a variety of financing sources by which the firm can achieve its target earnings.
  • Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.
By borrowing funds, the firm incurs a debt that must be paid. But, this debt is paid in small installments over a relatively long period of time. This frees funds for more immediate use in the stock market. For example, suppose a company can afford a new factory but will be left with negligible free cash. In that case, it may be better to finance the factory and spend the cash on hand on inputs, labor, or even hold a significant portion as a reserve against unforeseen circumstances.

The Risk of Financial Leverage

The most obvious and apparent risk of leverage is that if price changes unexpectedly, the leveraged position can lead to severe losses. For example, imagine a hedge fund seeded by $50 worth of investor money. The hedge fund borrows another $50 and buys an asset worth $100, leading to a leverage ratio of 2:1. For the investor, this is neither good nor bad -- until the asset price changes. If the asset price goes up 10 percent, the investor earns $10 on $50 of capital, a net gain of 20 percent, and is very pleased with the increased gains from the leverage. However, if the asset price crashes unexpectedly, say by 30 percent, the investor loses $30 on $50 of capital, suffering a 60 percent loss. In other words, the effect of leverage is to increase the volatility of returns and increase the effects of a price change on the asset to the bottom line while increasing the chance for profit as well.